1-甲基-4-(氯甲基)哌啶盐酸盐 | 1182284-45-2

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲基-4-(氯甲基)哌啶盐酸盐
• 英文名称: 4-(Chloromethyl)-1-methylpiperidine hydrochloride
• 英文别名: 4-(chloromethyl)-1-methylpiperidine;hydrochloride
• CAS: 1182284-45-2
• 化学式: C7H15Cl2N
• 分子量: 184.1
• InChiKey: NIXLUDKORJXUEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] TLR7/8 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE TLR7/8 ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2018031434A1

  公开（公告）日：2018-02-15

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.

  本发明涉及式I化合物及其药用可接受的组合物，用作TLR7/8拮抗剂。
• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• [EN] PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS<br/>[FR] PYRIDINOYLPIPERIDINES UTILISEES COMME AGONISTES DE 5-HT1F
  申请人：LILLY CO ELI

  公开号：WO2003084949A1

  公开（公告）日：2003-10-16

  The present invention relates to compounds of formula I:or pharmaceutically acceptable acid addition salts thereof, where;R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle;R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II II;R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl;R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

  本发明涉及以下公式的化合物：或其药学上可接受的酸盐，其中; R1是C1-C6烷基，取代的C1-C6烷基，C3-C7环烷基，取代的C3-C7环烷基，C3-C7环烷基-C1-C3烷基，取代的C3-C7环烷基-C1-C3烷基，苯基，取代的苯基，杂环，或取代的杂环; R2是氢，C1-C3烷基，C3-C6环烷基-C1-C3烷基，或公式II的基团 II; R3是氢或C1-C3烷基; R4是氢，卤素，或C1-C3烷基; R5是氢或C1-C3烷基; R6是氢或C1-C6烷基; n是从1到6的整数（包括1和6）。本发明的化合物可用于激活5-HT1F受体，抑制神经蛋白外渗，并用于哺乳动物偏头痛的治疗或预防。本发明还涉及一种合成公式I化合物合成中间体的方法。
• Pyridinoylpiperidines as 5-ht1f agonists
  申请人：Cohen Philip Michael

  公开号：US20050222206A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R 1 is C 1 -C 6 alkyl, substituted C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, substituted C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, substituted C 3 -C 7 cycloalkyl-C 1 -C 3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R 2 is hydrogen, C 1 -C 3 alkyl, C 3 -C 6 cycloalkyl-C 1 -C 3 alkyl, or a group of formula II R 3 is hydrogen or C 1 -C 3 alkyl; R 4 is hydrogen, halo, or C 1 -C 3 alkyl; R 5 is hydrogen or C 1 -C 3 alkyl; R 6 is hydrogen or C 1 -C 6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5 -HT 1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

  本发明涉及式I的化合物或其药学上可接受的酸加成盐，其中；R1是C1-C6烷基，取代的C1-C6烷基，C3-C7环烷基，取代的C3-C7环烷基，C3-C7环烷基-C1-C3烷基，取代的C3-C7环烷基-C1-C3烷基，苯基，取代的苯基，杂环或取代的杂环；R2是氢，C1-C3烷基，C3-C6环烷基-C1-C3烷基或IIR3的基团；R3是氢或C1-C3烷基；R4是氢，卤素或C1-C3烷基；R5是氢或C1-C3烷基；R6是氢或C1-C6烷基；n为1到6的整数，包括1和6。 本发明的化合物对于激活5-HT1F受体，抑制神经蛋白外渗以及治疗或预防哺乳动物偏头痛具有用处。本发明还涉及一种用于合成式I化合物中间体的合成过程。